CN112956649A - 防治老年痴呆复合制剂及其制备方法 - Google Patents
防治老年痴呆复合制剂及其制备方法 Download PDFInfo
- Publication number
- CN112956649A CN112956649A CN202110317645.8A CN202110317645A CN112956649A CN 112956649 A CN112956649 A CN 112956649A CN 202110317645 A CN202110317645 A CN 202110317645A CN 112956649 A CN112956649 A CN 112956649A
- Authority
- CN
- China
- Prior art keywords
- natto
- preparation
- phosphatidylserine
- parts
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 12
- 206010039966 Senile dementia Diseases 0.000 title claims abstract description 11
- 239000002131 composite material Substances 0.000 title claims description 3
- 235000013557 nattō Nutrition 0.000 claims abstract description 40
- 239000000843 powder Substances 0.000 claims abstract description 27
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims abstract description 23
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims abstract description 23
- 150000001875 compounds Chemical class 0.000 claims abstract description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 26
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 16
- 241000195493 Cryptophyta Species 0.000 claims description 14
- 235000019359 magnesium stearate Nutrition 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000004376 Sucralose Substances 0.000 claims description 9
- 239000000686 essence Substances 0.000 claims description 9
- 235000020183 skimmed milk Nutrition 0.000 claims description 9
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 9
- 235000019408 sucralose Nutrition 0.000 claims description 9
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000008347 soybean phospholipid Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 239000003094 microcapsule Substances 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 108010010779 glutamine-pyruvate aminotransferase Proteins 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 229920000858 Cyclodextrin Polymers 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 239000007779 soft material Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 3
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 210000004556 brain Anatomy 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 6
- 229940086319 nattokinase Drugs 0.000 abstract description 6
- 108010073682 nattokinase Proteins 0.000 abstract description 6
- 210000003792 cranial nerve Anatomy 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 4
- 210000004204 blood vessel Anatomy 0.000 abstract description 3
- 210000004958 brain cell Anatomy 0.000 abstract description 3
- 210000003710 cerebral cortex Anatomy 0.000 abstract description 3
- 208000007536 Thrombosis Diseases 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 19
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 18
- 239000003921 oil Substances 0.000 description 15
- 235000019198 oils Nutrition 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 9
- 238000012258 culturing Methods 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical group [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 description 4
- 239000013543 active substance Substances 0.000 description 3
- 229960003135 donepezil hydrochloride Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- ZYOCVAPRXVCQQR-UHFFFAOYSA-N Taraxasterone Chemical compound CC12CCC(=O)C(C)(C)C1CCC1(C)C2CCC2C3C(C)C(=C)CCC3(C)CCC21C ZYOCVAPRXVCQQR-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical class CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000006736 behavioral deficit Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019143 vitamin K2 Nutrition 0.000 description 1
- 239000011728 vitamin K2 Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/40—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the fats used
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Health & Medical Sciences (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于保健品食品领域，具体涉及防治老年痴呆复合制剂及其制备方法。由以下配方组成：纳豆粉6份、磷脂酰丝氨酸0.3份、DHA藻油12份、脱脂奶粉2份、食用香精0.01份、三氯蔗糖0.04份、硬脂酸镁0.7份，本发明的配方独创，采用纳豆粉与DHA藻油、磷脂酰丝氨酸混合配比，纳豆粉中有纳豆激酶，对血管的堵塞有一定的抑制作用，DHA藻油、磷脂酰丝氨酸对大脑皮层、脑神经有明显的益处，两者结合可以有效溶化血栓、活化大脑、提高记忆力和注意，修复受损伤脑细胞。
Description
技术领域
本发明属于保健品食品领域，具体涉及防治老年痴呆复合制剂及其制备方法。
背景技术
纳豆(Natto)是以大豆为原料，经纳豆枯草芽孢杆菌(Bacillus subtilisnatto)发酵制成的即食豆制品。纳豆富含蛋白质、有机酸、纤维素、钙、铁、多种维生素等营养物质。此外，纳豆还富含纳豆激酶、益生菌、吡啶二羧酸、血管紧张肽转化酶抑制剂、维生素K2等多种具保健功能的活性物质，这些营养成分及活性物质对人体健康有重要作用。纳豆主要盛行于日本，也流行于朝鲜、韩国及欧美国家。我国对纳豆的重视起步较晚，传统纳豆的制作以黄豆为原料，如今纳豆的原料越来越多样化，不少研究采用不同的豆类、杂粮进行发酵。这利于纳豆品种的多样化生产，满足不同人群的喜好。虽然纳豆营养价值高，但由于我国消费者对纳豆独特风味的排斥，纳豆在中国的推广并不理想。
DHA，二十二碳六烯酸，俗称脑黄金，是一种对人体非常重要的多不饱和脂肪酸，属于Omega-3不饱和脂肪酸家族中的重要成员。DHA是神经系统细胞生长及维持的一种主要元素，是大脑和视网膜的重要构成脂肪酸，在人体大脑皮层中含量高达20％，在眼睛视网膜中所占比例最大，约占50％。对婴儿智力和视力发育至关重要。DHA藻油提取自海洋微藻，未经食物链的传递，相对更安全，其EPA含量非常低。
磷脂酰丝氨酸(Phosphatidylserine)又称复合神经酸。简称PS，由天然大豆榨油剩余物提取。是细胞膜的活性物质，尤其存在于大脑细胞中。其功能主要是改善神经细胞功能，调节神经脉冲的传导，增进大脑记忆功能，由于其具有很强的亲脂性，吸收后能够迅速通过血脑屏障进入大脑，起到舒缓血管平滑肌细胞，增加脑部供血的作用。
老年痴呆是一种慢性、大脑原发性、以进行性认知功能低下和行为损害为特征的中枢神经系统退行性疾病，临床症状有认知障碍、记忆障碍、精神行为障碍、性格孤僻淡漠以及时间和空间定向能力障碍等，最终导致死亡，多在老年人中发生。迄今，世界上约有4700万人罹患老年痴呆，至2050年这个数字可能增长到1.31亿，该病也带来巨大的经济影响，全球在痴呆病上花费的金额多达8180亿美元，老年痴呆已成为世界公共卫生面临的主要挑战之一。我国是人口大国，随着人口老龄化进程的加快，该疾病的危害也越来越引起大家的重视。
发明内容
基于上述背景技术中的问题，本发明拟提供一种风味良好，能够预防老年痴呆症的保健品或食品。
本发明是通过以下方法来制备的：
防治老年痴呆复合制剂及其制备方法，由以下配方组成：纳豆粉、磷脂酰丝氨酸、DHA藻油、脱脂奶粉、食用香精、三氯蔗糖、硬脂酸镁。具体的配方为：纳豆粉5-8份、磷脂酰丝氨酸0.1-0.5份、DHA藻油10-15份、脱脂奶粉1-3份、食用香精0.01-0.0.2份、三氯蔗糖0.01-0.05份、硬脂酸镁0.5-1份。
具体的配方为：纳豆粉6份、磷脂酰丝氨酸0.3份、DHA藻油12份、脱脂奶粉2份、食用香精0.01份、三氯蔗糖0.04份、硬脂酸镁0.7份。
所述的复合制剂，制备方式由以下步骤组成：
(1)称取处方量的纳豆粉：将纳豆破碎至500目，加入纳豆3倍体积当量的壁材羟丙基甲基纤维素酞酸酯；加入固化剂谷氨酰胺转氨酶，用量为壁材质量的1.5％；采用喷雾干燥法进行干燥制粒，控制进风温度为85℃，制成目数为1000目的微囊制剂；
(2)称取处方量的磷脂酰丝氨酸、DHA藻油、大豆磷脂和D-甘露糖醇，先在湿法混合制粒机中加入纳豆微囊，再加入D-甘露糖醇，磷脂酰丝氨酸、最后加入大豆磷脂，开机混合5分钟；
(3)加入乙醇溶解的DHA藻油，加入重量份为5份的水，再加入处方量的环糊精开搅拌切碎刀制成软材，过16目筛网，60℃干燥到水份小于3％，16目整粒，加入处方量的硬脂酸镁混匀即可。
所述制剂可以是片剂、压片糖果剂、固体饮料剂、胶囊、粒剂、水剂中任意一种。
本发明的有益效果为：
(1)本发明的配方独创，采用纳豆粉与DHA藻油、磷脂酰丝氨酸混合配比，纳豆粉中有纳豆激酶，对血管的堵塞有一定的抑制作用，DHA藻油、磷脂酰丝氨酸对大脑皮层、脑神经有明显的益处，两者结合可以有效溶化血栓、活化大脑、提高记忆力和注意，修复受损伤脑细胞、打通大脑与血液循环之间障碍，维持脑神经细胞的正常功能，并增强大脑神经系统功能，进而达到预防老年性痴呆症的功效。
(2)针对纳豆激酶在胃液中容易失去活性的问题，本发明首次将其做成了肠溶性微囊，在经过胃时不会被消化，在到达人体小肠时可以充分的释放出来。
具体实施方式
以下实施例用于进一步阐述本发明，但不应理解为对本发明权利要求书请求保护范围的限制。
实施例1
防治老年痴呆复合制剂及其制备方法：纳豆粉6份、磷脂酰丝氨酸0.3份、DHA藻油12份、脱脂奶粉2份、食用香精0.01份、三氯蔗糖0.04份、硬脂酸镁0.7份。
制备方式由以下步骤组成：
(1)称取处方量的纳豆粉：将纳豆破碎至500目，加入纳豆3倍体积当量的壁材羟丙基甲基纤维素酞酸酯；加入固化剂谷氨酰胺转氨酶，用量为壁材质量的1.5％；采用喷雾干燥法进行干燥制粒，控制进风温度为85℃，制成目数为1000目的微囊制剂；
(2)称取处方量的磷脂酰丝氨酸、DHA藻油、大豆磷脂和D-甘露糖醇，先在湿法混合制粒机中加入纳豆微囊，再加入D-甘露糖醇，磷脂酰丝氨酸、最后加入大豆磷脂，开机混合5分钟；
(3)加入乙醇溶解的DHA藻油，加入重量份为5份的水，再加入处方量的环糊精开搅拌切碎刀制成软材，过16目筛网，60℃干燥到水份小于3％，16目整粒，加入处方量的硬脂酸镁混匀即可。
所述制剂可以是片剂、压片糖果剂、固体饮料剂、胶囊、粒剂、水剂中任意一种。
实施例2
配方为：纳豆粉5份、磷脂酰丝氨酸0.3份、DHA藻油12份、脱脂奶粉2份、食用香精0.01份、三氯蔗糖0.01份、硬脂酸镁0.5份。
其余制备步骤同实施例1。
实施例3
配方为：纳豆粉8份、磷脂酰丝氨酸0.5份、DHA藻油15份、脱脂奶粉3份、食用香精0.02份、三氯蔗糖0.05份、硬脂酸镁1份。制备方式为：
(1)称取处方量的纳豆粉、磷脂酰丝氨酸、DHA藻油、大豆磷脂和D-甘露糖醇，先在湿法混合制粒机中加入纳豆粉，再加入D-甘露糖醇，磷脂酰丝氨酸、最后加入大豆磷脂，开机混合5分钟；
(2)加入乙醇溶解的DHA藻油，加入重量份为5份的水，再加入处方量的环糊精开搅拌切碎刀制成软材，过16目筛网，60℃干燥到水份小于3％，16目整粒，加入处方量的硬脂酸镁混匀即可。
所述制剂可以是片剂、压片糖果剂、固体饮料剂、胶囊、粒剂、水剂中任意一种。
实验验证：
1、细胞培养
取出保存于液氮冷冻的大鼠神经胶质瘤细胞C6细胞株，迅速置于37℃水浴中振荡至细胞融化后，转入已加入培养基的离心管中，以1000rpm离心5min，弃去上清液，加入少量培养基并轻轻吹吸均匀，培养基为含有10％胎牛血清、1％双抗的RPMI-1640培养基，将细胞悬液移入培养皿，在37℃、5％CO2、饱和湿度条件下培养。
2、细胞模型的制备
将对数生长期的C6细胞制成浓度为2.0×105个/mL的细胞悬液，接种于96孔板中，每孔100μL，培养24h后，按照如下分组进行处理，每组5个复孔：
对照组：更换为新鲜培养基继续培养3h；
Aβ25-35组(模型组)：更换为新鲜培养基继续培养3h；
盐酸多奈哌齐组(阳性药组)：更换为含20μM盐酸多奈哌齐的新鲜培养基继续培养3h；
本发明实施例组：更换为含5、10、20、30μM蒲公英甾酮的新鲜培养基继续培养3h。
按照上述分组继续培养3h后，Aβ25-35组、盐酸多奈哌齐组、实施例1-3组添加终浓度为10μM的凝聚态Aβ25-35，对照组加入等体积溶媒，继续培养18h后，各组加入20μLMTT溶液(浓度为5mg/mL)，37℃下继续培养4h。
继续培养4h后，小心吸弃孔内上清液，每孔加入150μLDMSO，震荡10min，使结晶充分溶解；选择490nm波长，在酶联免疫检测仪上测定各孔光吸收值(OD值)，取5个复孔OD值平均数，计算细胞存活率，对照组记为100％。
实验结果
各组细胞存活率如表1所示
表1.本发明实施例1-3对Aβ25-35组诱导的细胞损伤的影响
与Aβ25-35组相比、本实施例1-3组细胞存活率显著升高。盐酸多奈哌齐是美国食品与药物管理局(FDA)批准的用于治疗阿尔茨海默病的药物。
Claims (5)
1.防治老年痴呆复合制剂及其制备方法，其特征在于由以下配方组成：纳豆粉、磷脂酰丝氨酸、DHA藻油、脱脂奶粉、食用香精、三氯蔗糖、硬脂酸镁。
2.根据权利要求1所述的配方，其特征在于，具体的配方为：纳豆粉5-8份、磷脂酰丝氨酸0.1-0.5份、DHA藻油10-15份、脱脂奶粉1-3份、食用香精0.01-0.0.2份、三氯蔗糖0.01-0.05份、硬脂酸镁0.5-1份。
3.根据权利要求2所述的配方，其特征在于，具体的配方为：纳豆粉6份、磷脂酰丝氨酸0.3份、DHA藻油12份、脱脂奶粉2份、食用香精0.01份、三氯蔗糖0.04份、硬脂酸镁0.7份。
4.根据权利要求2所述的复合制剂，其特征在于制备方式由以下步骤组成：
(1)称取处方量的纳豆粉：将纳豆破碎至500目，加入纳豆3倍体积当量的壁材羟丙基甲基纤维素酞酸酯；加入固化剂谷氨酰胺转氨酶，用量为壁材质量的1.5％；采用喷雾干燥法进行干燥制粒，控制进风温度为85℃，制成目数为1000目的微囊制剂；
(2)称取处方量的磷脂酰丝氨酸、DHA藻油、大豆磷脂和D-甘露糖醇，先在湿法混合制粒机中加入纳豆微囊，再加入D-甘露糖醇，磷脂酰丝氨酸、最后加入大豆磷脂，开机混合5分钟；
(3)加入乙醇溶解的DHA藻油，加入重量份为5份的水，再加入处方量的环糊精开搅拌切碎刀制成软材，过16目筛网，60℃干燥到水份小于3％，16目整粒，加入处方量的硬脂酸镁混匀即可。
5.根据权利要求1-4任意一项所述的复合制剂，其特征在于，所述制剂可以是片剂、压片糖果剂、固体饮料剂、胶囊、粒剂、水剂中任意一种。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110317645.8A CN112956649A (zh) | 2021-03-25 | 2021-03-25 | 防治老年痴呆复合制剂及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110317645.8A CN112956649A (zh) | 2021-03-25 | 2021-03-25 | 防治老年痴呆复合制剂及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112956649A true CN112956649A (zh) | 2021-06-15 |
Family
ID=76278424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110317645.8A Pending CN112956649A (zh) | 2021-03-25 | 2021-03-25 | 防治老年痴呆复合制剂及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112956649A (zh) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004537577A (ja) * | 2001-08-09 | 2004-12-16 | デグッサ フード イングレディエンツ ゲーエムベーハー | 温血動物のストレス状態の予防用及び治療用の（リゾ）ホスファチジルセリン含有製剤 |
| CN106509908A (zh) * | 2015-09-12 | 2017-03-22 | 石家庄以岭药业股份有限公司 | 一种含有磷脂酰丝氨酸咀嚼片及其制备方法 |
| CN106729280A (zh) * | 2016-12-27 | 2017-05-31 | 南京圣诺生物科技实业有限公司 | 一种含磷脂酰丝氨酸的组合物及其制备方法和应用 |
| CN107156832A (zh) * | 2017-05-31 | 2017-09-15 | 江苏朸健生命科技发展有限公司 | 一种改善记忆力的保健食品 |
| CN108308535A (zh) * | 2018-03-22 | 2018-07-24 | 武汉虹辰远荣生物制品有限公司 | 一种具有改善脑部神经功能的纳豆健康产品及其制备方法 |
| CN111728217A (zh) * | 2020-07-07 | 2020-10-02 | 江西邦泰绿色生物合成生态产业园发展有限公司 | 一种玛咖纳豆制品复合制剂及其制备方法 |
-
2021
- 2021-03-25 CN CN202110317645.8A patent/CN112956649A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004537577A (ja) * | 2001-08-09 | 2004-12-16 | デグッサ フード イングレディエンツ ゲーエムベーハー | 温血動物のストレス状態の予防用及び治療用の（リゾ）ホスファチジルセリン含有製剤 |
| CN106509908A (zh) * | 2015-09-12 | 2017-03-22 | 石家庄以岭药业股份有限公司 | 一种含有磷脂酰丝氨酸咀嚼片及其制备方法 |
| CN106729280A (zh) * | 2016-12-27 | 2017-05-31 | 南京圣诺生物科技实业有限公司 | 一种含磷脂酰丝氨酸的组合物及其制备方法和应用 |
| CN107156832A (zh) * | 2017-05-31 | 2017-09-15 | 江苏朸健生命科技发展有限公司 | 一种改善记忆力的保健食品 |
| CN108308535A (zh) * | 2018-03-22 | 2018-07-24 | 武汉虹辰远荣生物制品有限公司 | 一种具有改善脑部神经功能的纳豆健康产品及其制备方法 |
| CN111728217A (zh) * | 2020-07-07 | 2020-10-02 | 江西邦泰绿色生物合成生态产业园发展有限公司 | 一种玛咖纳豆制品复合制剂及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106135977B (zh) | 一种具有补钙明目功能的钙果粉的生产方法 | |
| CN104473249B (zh) | 一种松花粉的液体制剂及其制备方法 | |
| CN104982928B (zh) | 一种红豆杉果保健酵素及其制备方法 | |
| US20120077780A1 (en) | Fat Accumulation Inhibitor and Method of Use Thereof | |
| CN103190630A (zh) | 一种含有共轭亚油酸甘油酯的功能性蛋白质粉 | |
| JP2014047213A (ja) | カキと海藻類の混合物の発酵物を有効成分で含むストレス解消または睡眠障害改善用組成物及びその製造方法 | |
| CN113499401A (zh) | 一种治疗阿尔茨海默病的药物组合物及其制备方法和应用 | |
| CN108685006A (zh) | 一种欧米伽3固体饮料 | |
| CN101766274B (zh) | 含竹叶黄酮的抗氧化功能食品组合物 | |
| CN108968037A (zh) | 老年痴呆症全营养配方食品 | |
| KR20100122296A (ko) | 발효차를 함유하는 혈액 순환 개선용 조성물 및 이를 포함하는 약제학적 및 건강 식품 조성물 | |
| KR101597781B1 (ko) | 락토바실러스 브레비스 g-101 및 이의 용도 | |
| CN112956649A (zh) | 防治老年痴呆复合制剂及其制备方法 | |
| EP2612673B1 (en) | Intestine immunomodulator | |
| KR101515253B1 (ko) | 아디포넥틴 분비 촉진 및/또는 감소 억제제 | |
| CN107537028B (zh) | 一种同时辅助降血糖及降血压的配方及其制备方法 | |
| JP2011057642A (ja) | 神経突起伸展促進剤 | |
| KR20040083552A (ko) | 버섯 균사체를 이용한 발아 현미 가공식품 및 그제조방법 | |
| KR100692286B1 (ko) | 한약재와 정제 포도당을 주원료로 한 건강보조식품의제조방법 및 그 제품 | |
| KR101227922B1 (ko) | 파파야 퓌레 조제품 및 그 제조방법 | |
| KR20130022256A (ko) | 오디 두부 | |
| CN102370675A (zh) | 大叶冬青提取物为有效成分的药物组合物 | |
| CN108936577A (zh) | 一种具有心血管保护作用的天然可食用化合物群制备方法 | |
| WO2004073613A2 (en) | A medicine and food | |
| KR102604523B1 (ko) | 화살나무 귀전우 추출물과 마늘발효액을 이용한 인지기능 개선 건강기능식품 조성물 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210615 |
|
| RJ01 | Rejection of invention patent application after publication |